Based in Daejeon, South Korea, Promedigen has created a customized cancer-specific PPI drug platform and holds intellectual property rights for phosphorylated protein using SepRS and EF-Tu variant. Their technology enables the mass production of phosphorylated modified proteins, which can induce phosphorylation at specific locations. With their next-generation PPI drug discovery platform, Promedigen focuses on the research and development of new drugs for the treatment of cancer and neurodegenerative disorders.